Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel CMKLR1 Inhibitors for Application in Demyelinating Disease

9 May 2019

Abstract excerpt

Small molecules that disrupt leukocyte trafficking have proven effective in treating patients with multiple sclerosis (MS). We previously reported that chemerin receptor chemokine-like receptor 1 (CMKLR1) is required for maximal clinical and histological experimental autoimmune encephalomyelitis (EAE); and identified CMKLR1 small molecule antagonist 2-(α-naphthoyl) ethyltrimethylammonium iodide (α-NETA) that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Immune Cell Function and Interaction
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31073181
DOI: 10.1038/s41598-019-43428-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel CMKLR1 Inhibitors for Application in Demyelinating DiseasePMID 31073181Read ↗

Emerging small-molecule treatments for multiple sclerosis: focus on B cellsSemantic proximity Read ↗

Etifoxine inhibits NLRP3 inflammasome activity in human and murine myeloid cellsSemantic proximity Read ↗

Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphomaSemantic proximity Read ↗

ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2‐dependent migrationSemantic proximity Read ↗

Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential in progressive forms of multiple sclerosisSemantic proximity Read ↗

MOG-specific CAR Tregs: a novel approach to treat multiple sclerosisSemantic proximity Read ↗

Structure–Activity Relationship and Biological Investigation of a REV-ERBα-Selective Agonist SR-29065 (34) for Autoimmune DisordersSemantic proximity Read ↗

Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo EfficacySemantic proximity Read ↗

Dual Role of Ninjurin-1 in Myeloid Cell Adhesion and Inflammation in Relapse-Remitting EAESemantic proximity Read ↗

Bile Acid Scaffold Engineering Reveals an Androstane-Triol Derivative as a Potent Immunomodulator with Therapeutic Efficacy in EAESemantic proximity Read ↗

Efficacy of vafidemstat in experimental autoimmune encephalomyelitis highlights the KDM1A/RCOR1/HDAC epigenetic axis in multiple sclerosisSemantic proximity Read ↗

Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.